James Kihara Sells 4,000 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $22.50, for a total value of $90,000.00. Following the completion of the sale, the insider now directly owns 20,395 shares in the company, valued at $458,887.50. This trade represents a 16.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

James Kihara also recently made the following trade(s):

• On Friday, May 2nd, James Kihara sold 1,327 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $14.60, for a total value of $19,374.20.
• On Tuesday, April 8th, James Kihara sold 1,028 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $14.82, for a total value of $15,234.96.
• On Wednesday, March 26th, James Kihara sold 1,095 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $17.05, for a total value of $18,669.75.
• On Monday, February 24th, James Kihara sold 475 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $19.96, for a total value of $9,481.00.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock opened at $21.69 on Wednesday. The company has a market capitalization of $3.63 billion, a PE ratio of 27.81 and a beta of 0.47. ACADIA Pharmaceuticals Inc. has a one year low of $13.40 and a one year high of $25.23. The business has a 50 day simple moving average of $16.11 and a 200 day simple moving average of $17.19.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.01. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. During the same quarter in the previous year, the company posted $0.10 EPS. The business’s revenue for the quarter was up 18.7% compared to the same quarter last year. Equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Exchange Traded Concepts LLC bought a new position in ACADIA Pharmaceuticals in the 1st quarter valued at $29,000. Banque Transatlantique SA bought a new position in ACADIA Pharmaceuticals in the 1st quarter valued at $31,000. Picton Mahoney Asset Management bought a new position in ACADIA Pharmaceuticals in the 1st quarter valued at $32,000. Federated Hermes Inc. raised its position in ACADIA Pharmaceuticals by 231.5% in the 1st quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,618 shares during the last quarter. Finally, Virtus Fund Advisers LLC bought a new position in ACADIA Pharmaceuticals in the 4th quarter valued at $39,000. Institutional investors own 96.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ACAD. Oppenheimer reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Friday. HC Wainwright raised their price objective on ACADIA Pharmaceuticals from $27.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft began coverage on ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $26.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Monday. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.75.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.